Visual Impairment and Blindness Due to Macular Diseases Globally: A Systematic Review and Meta-Analysis
To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy. Meta-analysis. Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology Jg. 158; H. 4; S. 808 - 815 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Elsevier Inc
01.10.2014
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 0002-9394, 1879-1891, 1879-1891 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.
Meta-analysis.
Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded.
In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively.
In 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease. |
|---|---|
| AbstractList | To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.
Meta-analysis.
Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded.
In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively.
In 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease. Purpose To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy. Design Meta-analysis. Methods Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded. Results In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively. Conclusions In 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease. Purpose To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy. Design Meta-analysis. Methods Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, >=3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded. Results In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval : 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively. Conclusions In 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease. To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.PURPOSETo estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.Meta-analysis.DESIGNMeta-analysis.Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded.METHODSBased on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded.In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively.RESULTSIn 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively.In 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease.CONCLUSIONSIn 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease. |
| Author | Wong, Tien Y. Keeffe, Jill Price, Holly Resnikoff, Serge Leasher, Janet Taylor, Hugh R. Jonas, Jost B. Bourne, Rupert R.A. Pesudovs, Konrad White, Richard A. Flaxman, Seth R. Naidoo, Kovin |
| Author_xml | – sequence: 1 givenname: Jost B. orcidid: 0000-0003-2972-5227 surname: Jonas fullname: Jonas, Jost B. email: Jost.Jonas@medma.uni-heidelberg.de organization: Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany – sequence: 2 givenname: Rupert R.A. surname: Bourne fullname: Bourne, Rupert R.A. organization: Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom – sequence: 3 givenname: Richard A. surname: White fullname: White, Richard A. organization: Department of Genes and Environment, Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway – sequence: 4 givenname: Seth R. surname: Flaxman fullname: Flaxman, Seth R. organization: School of Computer Science and Heinz College, Carnegie Mellon University, Pittsburgh, Pennsylvania – sequence: 5 givenname: Jill orcidid: 0000-0001-5939-724X surname: Keeffe fullname: Keeffe, Jill organization: L.V. Prasad Eye Institute, Hyderabad, India – sequence: 6 givenname: Janet surname: Leasher fullname: Leasher, Janet organization: Nova South Eastern University, Fort Lauderdale, Florida – sequence: 7 givenname: Kovin surname: Naidoo fullname: Naidoo, Kovin organization: African Vision Research Institute, University of Kwazulu-Natal, South Africa, and the Brien Holden Vision Institute, Sydney, Australia – sequence: 8 givenname: Konrad orcidid: 0000-0002-6322-9369 surname: Pesudovs fullname: Pesudovs, Konrad organization: NHMRC Centre for Clinical Eye Research, Flinders University, Adelaide, Australia – sequence: 9 givenname: Holly surname: Price fullname: Price, Holly organization: Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom – sequence: 10 givenname: Tien Y. surname: Wong fullname: Wong, Tien Y. organization: Singapore Eye Research Institute, Singapore – sequence: 11 givenname: Serge surname: Resnikoff fullname: Resnikoff, Serge organization: Brien Holden Vision Institute, Sydney, Australia – sequence: 12 givenname: Hugh R. surname: Taylor fullname: Taylor, Hugh R. organization: Melbourne School of Population and Global Health, University of Melbourne, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24973605$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl9rFDEUxYNU7Lb6AXyRgC--zJh_k0wUhLXVWmgRrPoaspm7kjUzsyYZZb69WbcqLFifQuB3TnLPuSfoaBgHQOgxJTUlVD7f1HYz1oxQURNZE8ruoQVtla5oq-kRWhBCWKW5FsfoJKVNuUol1AN0zIRWXJJmgb589mmyAV_2W-tjD0PGdujw6-CHboCU8PkEOI_42rop2IjPfQKbIOGLMK5sCPMLvMQ3c8rQ2-wd_gDfPfz45XEN2VbLwYY5-fQQ3V_bkODR7XmKPr198_HsXXX1_uLybHlVuaaRueKdpp10HdFKM74WrW2YotpZxnhLqGqUBt1qAWUQQZTqKHOgm9VKtpRoYfkperb33cbx2wQpm94nByHYAcYpGdpIJjjVvCno0wN0M06x_LdQUrRESclVoZ7cUtOqh85so-9tnM3vCAtA94CLY0oR1n8QSsyuJrMxpSazq8kQaUpNRaMONM7nkt845Gh9uFP5cq-EEmKJOprkPAwOOh_BZdON_k71qwO1K0V7Z8NXmCH9nd8kZoi52S3Qbn-oIIQ3WhYD_W-D_zz-Ezl20Sw |
| CODEN | AJOPAA |
| CitedBy_id | crossref_primary_10_1111_ceo_13462 crossref_primary_10_1371_journal_pone_0162229 crossref_primary_10_1080_08164622_2021_1878820 crossref_primary_10_1039_D1BM01946E crossref_primary_10_1016_S2468_2667_20_30254_1 crossref_primary_10_1016_j_oftal_2023_07_015 crossref_primary_10_1080_13816810_2019_1633549 crossref_primary_10_1080_17425247_2019_1618829 crossref_primary_10_3389_fnins_2020_00755 crossref_primary_10_1097_MD_0000000000019007 crossref_primary_10_1007_s13369_024_09137_9 crossref_primary_10_1177_11206721221090700 crossref_primary_10_1111_ceo_12804 crossref_primary_10_26508_lsa_202101047 crossref_primary_10_1007_s00521_023_08249_x crossref_primary_10_1038_s41433_019_0439_6 crossref_primary_10_2147_JMDH_S433405 crossref_primary_10_5318_wjo_v5_i2_45 crossref_primary_10_1016_j_ophtha_2017_03_057 crossref_primary_10_1016_j_oret_2023_08_013 crossref_primary_10_1038_s41572_021_00265_2 crossref_primary_10_1016_j_measurement_2018_02_021 crossref_primary_10_22608_APO_2017251 crossref_primary_10_1016_j_oftale_2023_07_007 crossref_primary_10_1186_s12889_024_21047_x crossref_primary_10_1186_s40942_025_00656_7 crossref_primary_10_1186_s12886_018_0807_1 crossref_primary_10_3389_fncel_2023_1305896 crossref_primary_10_1177_1120672121998900 crossref_primary_10_1186_s12886_016_0348_4 crossref_primary_10_1371_journal_pone_0298960 crossref_primary_10_1097_MD_0000000000006405 crossref_primary_10_3390_mi11100929 crossref_primary_10_1016_j_ophtha_2015_12_030 crossref_primary_10_1080_02713683_2019_1576907 crossref_primary_10_1016_j_ophtha_2017_06_001 crossref_primary_10_12688_f1000research_123815_1 crossref_primary_10_1109_ACCESS_2020_3040275 crossref_primary_10_1177_1120672120927256 crossref_primary_10_1007_s00347_023_01983_6 crossref_primary_10_1111_jpi_12430 crossref_primary_10_1038_s41598_017_00741_4 crossref_primary_10_11124_JBISRIR_2017_003419 crossref_primary_10_1007_s00038_017_1000_7 crossref_primary_10_1021_acsbiomaterials_6b00757 crossref_primary_10_1088_1402_4896_adc51e crossref_primary_10_1109_TBME_2019_2915255 crossref_primary_10_3389_fmed_2022_854629 crossref_primary_10_1016_j_ijpsycho_2021_01_021 crossref_primary_10_1016_j_survophthal_2019_02_003 crossref_primary_10_1007_s12247_022_09638_w crossref_primary_10_1002_jemt_23020 crossref_primary_10_1167_iovs_18_26234 crossref_primary_10_1109_ACCESS_2023_3257720 crossref_primary_10_1007_s00018_019_03419_4 crossref_primary_10_1016_j_bspc_2022_103768 crossref_primary_10_2147_OPTH_S514480 crossref_primary_10_3390_jcm10153297 crossref_primary_10_15252_emmm_201911754 crossref_primary_10_1523_JNEUROSCI_2717_16_2017 crossref_primary_10_1007_s00417_016_3411_1 |
| Cites_doi | 10.1016/S0161-6420(92)31871-8 10.1056/NEJMoa1102673 10.1016/j.ophtha.2006.04.022 10.1016/S0140-6736(12)61689-4 10.1016/j.ophtha.2009.10.007 10.1016/j.ophtha.2011.09.027 10.1016/j.ophtha.2007.03.008 10.1016/S2214-109X(13)70145-1 10.1056/NEJMoa054481 10.1186/1471-2415-11-10 10.1056/NEJMoa062655 10.1016/j.ophtha.2006.01.035 10.1016/S0161-6420(95)30846-9 10.1016/j.ophtha.2013.05.025 10.1016/S0161-6420(99)90267-1 |
| ContentType | Journal Article |
| Copyright | 2014 Elsevier Inc. Elsevier Inc. Copyright © 2014 Elsevier Inc. All rights reserved. Copyright Elsevier Limited Oct 2014 |
| Copyright_xml | – notice: 2014 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2014 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Oct 2014 |
| CorporateAuthor | Vision Loss Expert Group of the Global Burden of Disease Study |
| CorporateAuthor_xml | – name: Vision Loss Expert Group of the Global Burden of Disease Study |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
| DOI | 10.1016/j.ajo.2014.06.012 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1879-1891 |
| EndPage | 815 |
| ExternalDocumentID | 3568669051 24973605 10_1016_j_ajo_2014_06_012 S0002939414003596 1_s2_0_S0002939414003596 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GeographicLocations | Europe Sub-Saharan Africa |
| GeographicLocations_xml | – name: Sub-Saharan Africa – name: Europe |
| GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ AABNK AAEDT AAEDW AAHTB AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQX ABDPE ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABPEJ ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACNCT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N4W N9A O-L O9- OAUVE OF- OPF OQ~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSZ SV3 T5K UNMZH UV1 VH1 WH7 WOW X7M XPP Z5R ZGI ZXP ~G- ~HD 3V. 7RV 7X7 8FI AACTN AFCTW AFKRA AFKWA AJOXV AMFUW AZQEC BENPR FYUFA GUQSH M1P M2O PKN RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU G8K LCYCR ZA5 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c556t-3d91d6cd097923f48a52719ca2238017579e9894e6744077d12ce95bb681094a3 |
| ISICitedReferencesCount | 81 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000342552900022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0002-9394 1879-1891 |
| IngestDate | Sat Sep 27 18:17:41 EDT 2025 Mon Oct 06 18:31:15 EDT 2025 Wed Jul 30 01:46:51 EDT 2025 Sat Nov 29 07:28:36 EST 2025 Tue Nov 18 22:24:04 EST 2025 Fri Feb 23 02:29:06 EST 2024 Sun Feb 23 10:19:44 EST 2025 Tue Oct 14 19:30:42 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2014 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c556t-3d91d6cd097923f48a52719ca2238017579e9894e6744077d12ce95bb681094a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| ORCID | 0000-0002-6322-9369 0000-0001-5939-724X 0000-0003-2972-5227 |
| PMID | 24973605 |
| PQID | 1648076637 |
| PQPubID | 41749 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1562431935 proquest_journals_1648076637 pubmed_primary_24973605 crossref_primary_10_1016_j_ajo_2014_06_012 crossref_citationtrail_10_1016_j_ajo_2014_06_012 elsevier_sciencedirect_doi_10_1016_j_ajo_2014_06_012 elsevier_clinicalkeyesjournals_1_s2_0_S0002939414003596 elsevier_clinicalkey_doi_10_1016_j_ajo_2014_06_012 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-10-01 |
| PublicationDateYYYYMMDD | 2014-10-01 |
| PublicationDate_xml | – month: 10 year: 2014 text: 2014-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Chicago |
| PublicationTitle | American journal of ophthalmology |
| PublicationTitleAlternate | Am J Ophthalmol |
| PublicationYear | 2014 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Mitchell, Smith, Attebo, Wang (bib5) 1995; 102 Rosenfeld, Brown, Heier (bib1) 2006; 355 CATT Research Group, Martin, Maguire (bib3) 2011; 364 Murray, Vos, Lozano (bib12) 2012; 380 Iwase, Araie, Tomidokoro (bib17) 2006; 113 Bourne, Stevens, White (bib11) 2013 Kawasaki, Yasuda, Song (bib8) 2010; 117 Stevens, White, Flaxman (bib10) 2013; 120 Rudnicka, Jarrar, Wormald, Cook, Fletcher, Owen (bib15) 2012; 119 Xu, Wang, Li (bib16) 2006; 113 Wong, Su, Li (bib9) 2014; 2 Klein, Klein, Linton (bib4) 1992; 99 Klaver, Assink, van Leeuwen (bib6) 2001; 42 Brown, Kaiser, Michels (bib2) 2006; 355 Ahmad, Boschi-Pinto, Lopez, Murray, Lozano, Inoue (bib13) 2001 Friedman, Katz, Bressler, Rahmani, Tielsch (bib14) 1999; 106 Wong, Chakravarthy, Klein (bib7) 2008; 115 Wu, Sun, Zhou, Weng (bib18) 2011; 11 Klein (10.1016/j.ajo.2014.06.012_bib4) 1992; 99 Mitchell (10.1016/j.ajo.2014.06.012_bib5) 1995; 102 Wong (10.1016/j.ajo.2014.06.012_bib7) 2008; 115 Brown (10.1016/j.ajo.2014.06.012_bib2) 2006; 355 Iwase (10.1016/j.ajo.2014.06.012_bib17) 2006; 113 Murray (10.1016/j.ajo.2014.06.012_bib12) 2012; 380 Wu (10.1016/j.ajo.2014.06.012_bib18) 2011; 11 Klaver (10.1016/j.ajo.2014.06.012_bib6) 2001; 42 Ahmad (10.1016/j.ajo.2014.06.012_bib13) 2001 Stevens (10.1016/j.ajo.2014.06.012_bib10) 2013; 120 Kawasaki (10.1016/j.ajo.2014.06.012_bib8) 2010; 117 Wong (10.1016/j.ajo.2014.06.012_bib9) 2014; 2 Xu (10.1016/j.ajo.2014.06.012_bib16) 2006; 113 Friedman (10.1016/j.ajo.2014.06.012_bib14) 1999; 106 Rudnicka (10.1016/j.ajo.2014.06.012_bib15) 2012; 119 Rosenfeld (10.1016/j.ajo.2014.06.012_bib1) 2006; 355 CATT Research Group (10.1016/j.ajo.2014.06.012_bib3) 2011; 364 Bourne (10.1016/j.ajo.2014.06.012_bib11) 2013 |
| References_xml | – volume: 113 start-page: 1141 year: 2006 ident: bib16 article-title: Causes of blindness and visual impairment in an urban and rural area in Beijing: the Beijing Eye Study publication-title: Ophthalmology – volume: 120 start-page: 2377 year: 2013 end-page: 2384 ident: bib10 article-title: Global prevalence of visual impairment and blindness: magnitude and temporal trends, 1990-2010 publication-title: Ophthalmology – volume: 355 start-page: 1419 year: 2006 end-page: 1431 ident: bib1 article-title: Ranibizumab for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 364 start-page: 1897 year: 2011 end-page: 1908 ident: bib3 article-title: Ranibizumab and bevacizumab for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 102 start-page: 1450 year: 1995 end-page: 1460 ident: bib5 article-title: Prevalence of age-related maculopathy in Australia: The Blue Mountains Eye Study publication-title: Ophthalmology – year: 2013 ident: bib11 article-title: Causes of global visual loss: 1990-2010. The Global Burden of Disease Study publication-title: Lancet Global Health – volume: 380 start-page: 2197 year: 2012 end-page: 2223 ident: bib12 article-title: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 publication-title: Lancet – volume: 355 start-page: 1432 year: 2006 end-page: 1444 ident: bib2 article-title: Ranibizumab versus verteporfin for neovascular age-related macular degeneration publication-title: N Engl J Med – volume: 2 start-page: e106 year: 2014 end-page: e116 ident: bib9 article-title: Global prevalence and burden of age-related macular degeneration: a meta-analysis and disease burden projection for 2020 and 2040 publication-title: Lancet Global Health – volume: 119 start-page: 571 year: 2012 end-page: 580 ident: bib15 article-title: Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis publication-title: Ophthalmology – volume: 106 start-page: 1049 year: 1999 end-page: 1055 ident: bib14 article-title: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey publication-title: Ophthalmology – volume: 117 start-page: 921 year: 2010 end-page: 927 ident: bib8 article-title: The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis publication-title: Ophthalmology – volume: 42 start-page: 2237 year: 2001 end-page: 2241 ident: bib6 article-title: Incidence and progression rates of age-related maculopathy: the Rotterdam Study publication-title: Invest Ophthalmol Vis Sci – volume: 11 start-page: 10 year: 2011 ident: bib18 article-title: Causes and 3-year-incidence of blindness in Jing-An District, Shanghai, China 2001-2009 publication-title: BMC Ophthalmol – year: 2001 ident: bib13 article-title: Age standardization of rates: a new WHO standard. GPE Discussion Paper Series No. 31. EIP/GPE/EBD – volume: 99 start-page: 933 year: 1992 end-page: 943 ident: bib4 article-title: Prevalence of age-related maculopathy: The Beaver Dam Eye Study publication-title: Ophthalmology – volume: 115 start-page: 116 year: 2008 end-page: 126 ident: bib7 article-title: The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis publication-title: Ophthalmology – volume: 113 start-page: 1354 year: 2006 end-page: 1362 ident: bib17 article-title: Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study publication-title: Ophthalmology – volume: 99 start-page: 933 issue: 6 year: 1992 ident: 10.1016/j.ajo.2014.06.012_bib4 article-title: Prevalence of age-related maculopathy: The Beaver Dam Eye Study publication-title: Ophthalmology doi: 10.1016/S0161-6420(92)31871-8 – volume: 364 start-page: 1897 issue: 20 year: 2011 ident: 10.1016/j.ajo.2014.06.012_bib3 article-title: Ranibizumab and bevacizumab for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa1102673 – volume: 113 start-page: 1354 issue: 8 year: 2006 ident: 10.1016/j.ajo.2014.06.012_bib17 article-title: Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2006.04.022 – volume: 380 start-page: 2197 issue: 9859 year: 2012 ident: 10.1016/j.ajo.2014.06.012_bib12 article-title: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 publication-title: Lancet doi: 10.1016/S0140-6736(12)61689-4 – volume: 117 start-page: 921 issue: 5 year: 2010 ident: 10.1016/j.ajo.2014.06.012_bib8 article-title: The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.10.007 – volume: 119 start-page: 571 issue: 3 year: 2012 ident: 10.1016/j.ajo.2014.06.012_bib15 article-title: Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.09.027 – volume: 115 start-page: 116 issue: 1 year: 2008 ident: 10.1016/j.ajo.2014.06.012_bib7 article-title: The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2007.03.008 – volume: 2 start-page: e106 year: 2014 ident: 10.1016/j.ajo.2014.06.012_bib9 article-title: Global prevalence and burden of age-related macular degeneration: a meta-analysis and disease burden projection for 2020 and 2040 publication-title: Lancet Global Health doi: 10.1016/S2214-109X(13)70145-1 – volume: 355 start-page: 1419 issue: 14 year: 2006 ident: 10.1016/j.ajo.2014.06.012_bib1 article-title: Ranibizumab for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 42 start-page: 2237 issue: 10 year: 2001 ident: 10.1016/j.ajo.2014.06.012_bib6 article-title: Incidence and progression rates of age-related maculopathy: the Rotterdam Study publication-title: Invest Ophthalmol Vis Sci – volume: 11 start-page: 10 year: 2011 ident: 10.1016/j.ajo.2014.06.012_bib18 article-title: Causes and 3-year-incidence of blindness in Jing-An District, Shanghai, China 2001-2009 publication-title: BMC Ophthalmol doi: 10.1186/1471-2415-11-10 – volume: 355 start-page: 1432 issue: 14 year: 2006 ident: 10.1016/j.ajo.2014.06.012_bib2 article-title: Ranibizumab versus verteporfin for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa062655 – year: 2013 ident: 10.1016/j.ajo.2014.06.012_bib11 article-title: Causes of global visual loss: 1990-2010. The Global Burden of Disease Study publication-title: Lancet Global Health – volume: 113 start-page: 1141 issue: 7 year: 2006 ident: 10.1016/j.ajo.2014.06.012_bib16 article-title: Causes of blindness and visual impairment in an urban and rural area in Beijing: the Beijing Eye Study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2006.01.035 – year: 2001 ident: 10.1016/j.ajo.2014.06.012_bib13 – volume: 102 start-page: 1450 issue: 10 year: 1995 ident: 10.1016/j.ajo.2014.06.012_bib5 article-title: Prevalence of age-related maculopathy in Australia: The Blue Mountains Eye Study publication-title: Ophthalmology doi: 10.1016/S0161-6420(95)30846-9 – volume: 120 start-page: 2377 issue: 12 year: 2013 ident: 10.1016/j.ajo.2014.06.012_bib10 article-title: Global prevalence of visual impairment and blindness: magnitude and temporal trends, 1990-2010 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.05.025 – volume: 106 start-page: 1049 issue: 6 year: 1999 ident: 10.1016/j.ajo.2014.06.012_bib14 article-title: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey publication-title: Ophthalmology doi: 10.1016/S0161-6420(99)90267-1 |
| SSID | ssj0006747 |
| Score | 2.440521 |
| SecondaryResourceType | review_article |
| Snippet | To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.
Meta-analysis.
Based on the... Purpose To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy. Design Meta-analysis.... To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.PURPOSETo estimate the number... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 808 |
| SubjectTerms | Age Blindness Blindness - epidemiology Diabetes Diabetic retinopathy Disease Global Health - statistics & numerical data Humans Macula Lutea Macular degeneration Ophthalmology Persons with Visual Disabilities - statistics & numerical data Population Prevalence Public health Retinal Diseases - epidemiology Studies Vision, Low - epidemiology Visual Acuity Visual impairment |
| Title | Visual Impairment and Blindness Due to Macular Diseases Globally: A Systematic Review and Meta-Analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0002939414003596 https://www.clinicalkey.es/playcontent/1-s2.0-S0002939414003596 https://dx.doi.org/10.1016/j.ajo.2014.06.012 https://www.ncbi.nlm.nih.gov/pubmed/24973605 https://www.proquest.com/docview/1648076637 https://www.proquest.com/docview/1562431935 |
| Volume | 158 |
| WOSCitedRecordID | wos000342552900022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-1891 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006747 issn: 0002-9394 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DiFeEN8UxmQknqhSNYkT27x1bBND2oS2gfoWuYmztipt1aTT-Nv45zjHH0kZGx8SL1GUxEnk-9m-O9_9DqE3YV-kqRxRL45p5hGa5d5IhLmXj1gkVG6nyEVVbIKenLDhkH9qtb7bXJjLGZ3P2dUVX_5XUcM1ELZKnf0LcbuXwgU4B6HDEcQOxz8S_JdJoVJCjmCcT1YuhHwP1Mmsmtb211W1jGOhI1D39Q5N0dXs_7NvOlf9rGZ4Ntz7VUSGLIVneUyaeq3b-GkwUSyW43IsZl83HPfKW2-3HsruXs-5A5xz9XS9lKuye9ob9OoVw1TxMzQA3frW4Uw4J64sx9Cs6cfwiYuIM841m2CzEf9ZTdg81HWQe1LP0Yxyz2e6yJebxCPWQCtpTMmsz5qru04evbZwaB_GtCemKiPUJxWpqwnw3uTjPlP_pH4JTFPFfxhvoe2ARpy10fbg6GD40SkCMSXUWl-qgd1Ur8ILf_rQTWrRTWZPpf6cP0D3jd2CBxpvD1FLzh-hu8cmMuMxutCwwzXsMAAGO9hhgB0uF9jADlvYYQu7d3iAa9BhDbrqHRuge4I-Hx6cv__gmSIeXhpFcemFGfezOM36XDFV5oSJKKA-TwXopaAd0YhyqYoAyFhRVVKa-UEqeTQaKaI8TkT4FLXni7l8jjDLKGEpy9OYShLRXAhCMgoKfcQEi3PWQX3bh0lqGO5VoZVZYkMZpwl0e6K6PVHhnH7QQW9dk6Wmd7nt4cAKJrF5y7DSJoCh2xrRXzWShRmPReInRZD0k2u46iDiWhp1WKu5v_vgjsVMUn8jVtQRYF3QDnrtbsNKorYHxVwu1vAMmEJgTvAw6qBnGmuuTwLCaRj3oxf_9k8v0b16yO-gdrlay1foTnpZTorVLtqiQ7ZrRs8PH5307A |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Visual+Impairment+and+Blindness+Due+to+Macular+Diseases+Globally%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=American+journal+of+ophthalmology&rft.au=Jonas%2C+Jost+B.&rft.au=Bourne%2C+Rupert+R.A.&rft.au=White%2C+Richard+A.&rft.au=Flaxman%2C+Seth+R.&rft.date=2014-10-01&rft.pub=Elsevier+Inc&rft.issn=0002-9394&rft.eissn=1879-1891&rft.volume=158&rft.issue=4&rft.spage=808&rft.epage=815&rft_id=info:doi/10.1016%2Fj.ajo.2014.06.012&rft.externalDocID=S0002939414003596 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029394%2FS0002939413X00212%2Fcov150h.gif |